Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Net Cash Flow (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Net Cash Flow for 6 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 107.71% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.9 million, a 88.7% increase, with the full-year FY2025 number at -$3.9 million, up 88.7% from a year prior.
  • Net Cash Flow was $1.2 million for Q4 2025 at Caribou Biosciences, up from -$14.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $305.8 million in Q3 2021 to a low of -$194.9 million in Q4 2021.
  • A 5-year average of -$177750.0 and a median of -$8.7 million in 2024 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 3662.69% in 2021; the steepest drop was 2167.74% in 2021.
  • Caribou Biosciences' Net Cash Flow stood at -$194.9 million in 2021, then skyrocketed by 87.82% to -$23.7 million in 2022, then plummeted by 122.75% to -$52.9 million in 2023, then surged by 70.36% to -$15.7 million in 2024, then skyrocketed by 107.71% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Net Cash Flow are $1.2 million (Q4 2025), -$14.0 million (Q3 2025), and -$4.2 million (Q2 2025).